Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge?

• Some investors may be wondering if Amneal Pharmaceuticals at around US$12.80 is still reasonably priced after a strong run, or if the easier gains are already behind it.
• The stock has recent returns of 1.2% over 7 days, 3.0% over 30 days, 1.1% year to date and 65.4% over the last year, with a very large 3 year gain and a 121.5% return over 5 years.
• Recent coverage has focused on Amneal Pharmaceuticals as a generic and specialty pharmaceuticals player, with attention on its role in supplying treatments and its position in a competitive US market. This context helps frame how investors are considering both its opportunities and its risks at current prices.
• On Simply Wall St’s 6 point valuation checklist, Amneal Pharmaceuticals scores a 3 out of 6. The next sections explain what that means across different valuation methods and suggest a broader way to think about value that goes beyond the headline numbers.

Amneal Pharmaceuticals delivered 65.4% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Amneal Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and then discounting those back to the present.

For Amneal Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $244.9 million. Simply Wall St then projects future free cash flows, using a mix of analyst estimates and extrapolated figures, with free cash flow for 2028 expected at $554 million and further projections running out to 2035.

Bringing all those projected cash flows back to today results in an estimated intrinsic value of about $48.82 per share. Compared with the recent share price around US$12.80, the model suggests the stock is trading at a 73.8% discount to this intrinsic value. This indicates it may be significantly undervalued on these cash flow assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Amneal Pharmaceuticals is undervalued by 73.8%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Amneal Pharmaceuticals.

Approach 2: Amneal Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings, which many investors find intuitive when comparing different stocks. A higher or lower P/E often reflects what the market is pricing in for future growth and how much risk it sees in those earnings, so a “normal” or “fair” P/E tends to rise with stronger growth expectations and fall when uncertainty or risk is higher.

Amneal Pharmaceuticals currently trades on a P/E of 56.67x. That stands above the Pharmaceuticals industry average P/E of 15.84x and also above the peer group average of 30.30x. Simply Wall St goes a step further with its proprietary “Fair Ratio,” which estimates what a more tailored P/E might look like, given factors such as the company’s earnings growth profile, industry, profit margins, market cap and specific risks. For Amneal Pharmaceuticals, this Fair Ratio is 30.42x.

This Fair Ratio aims to be more informative than a simple comparison with peers or the broad industry because it adjusts for company specific characteristics rather than treating all businesses as identical. Comparing the Fair Ratio of 30.42x with the current P/E of 56.67x suggests the shares trade at a richer multiple than this tailored benchmark.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Amneal Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you turn your view of Amneal Pharmaceuticals into a clear story that links what you think about its product mix, debt, US generics exposure and inhalation entry to a set of revenue, earnings and margin forecasts, a fair value, and then a simple comparison with today’s share price. Each Narrative updates as new news or earnings arrive. One investor might build a more optimistic view that aligns with the higher analyst price target of US$19.00, while another might lean closer to the lower US$15.00 target, and you can see both stories side by side to decide which assumptions you find more convincing.

Do you think there’s more to the story for Amneal Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com